Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 11/20 | 0.45 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.39 |
| ▸ | RAF1 | P04049 | 2/20 | 0.38 |
| ▸ | BRAF | P15056 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8173845 | 0.89 | PTK2 (0.41) | ROCK1PTK2ROCK2ALOX5MAOB | |
| SCHEMBL8174088 | 0.87 | ROCK1 (0.47) | ROCK1ROCK2 | |
| SCHEMBL8171335 | 0.87 | ROCK1 (0.46) | ROCK1PTK2ROCK2 | |
| SCHEMBL8166917 | 0.85 | ROCK1 (0.44) | ROCK1PTK2ROCK2 | |
| SCHEMBL8166227 | 0.85 | ROCK1 (0.44) | ROCK1ROCK2 | |
| SCHEMBL8179482 | 0.85 | PTK2 (0.40) | ROCK1PTK2ROCK2ALOX5MAOB | |
| SCHEMBL8173698 | 0.83 | PTK2 (0.41) | PTK2ALOX5MAOBMTNR1AMTNR1B | |
| SCHEMBL8172938 | 0.82 | ROCK1 (0.40) | ROCK1ROCK2MAOB | |
| SCHEMBL8173430 | 0.81 | ROCK1 (0.39) | ROCK1ROCK2 | |
| SCHEMBL2257284 | 0.80 | NPC1 (0.53) | ROCK1ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2155728-B1 | HETEROCYCLIC INDAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-07-29 | — | — | EP | claimed |
| EP-2155728-B1 | HETEROCYCLIC INDAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-07-29 | — | — | EP | disclosed |
| EP-2155728-B1 | HETEROCYCLIC INDAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-07-29 | — | — | EP | disclosed |
| US-8334309-B2 | Heterocyclic indazole derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-12-18 | — | — | US | disclosed |
| US-20110190355-A1 | HETEROCYCLIC INDAZOLE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-08-04 | — | — | US | disclosed |
| WO-2008138448-A2 | HETEROCYCLIC INDAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190355-A1 | HETEROCYCLIC INDAZOLE DERIVATIVES | SGK3, SGK2, SGK1 | ROCK1 576/4885PTK2 178/4885ROCK2 842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.